China Eastern Airlines Limited (CEA) Forms $41.15 Double Top; 3 Analysts Covering vTv Therapeutics Inc. (VTVT)

China Eastern Airlines Corporation Limited (CEA) formed double top with $44.85 target or 9.00% above today’s $41.15 share price. China Eastern Airlines Corporation Limited (CEA) has $16.84B valuation. The stock decreased 0.93% or $0.39 during the last trading session, reaching $41.15. About 18,250 shares traded. China Eastern Airlines Corporation Limited (NYSE:CEA) has risen 6.69% since March 3, 2017 and is uptrending. It has underperformed by 10.01% the S&P500.

Among 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. vTv Therapeutics Inc had 3 analyst reports since August 24, 2015 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Friday, September 4. Piper Jaffray initiated the shares of VTVT in report on Monday, August 24 with “Overweight” rating. Stifel Nicolaus initiated it with “Buy” rating and $17 target in Monday, August 24 report. See vTv Therapeutics Inc. (NASDAQ:VTVT) latest ratings:

Among 2 analysts covering China Eastern Airlines (NYSE:CEA), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. China Eastern Airlines had 3 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of China Eastern Airlines Corporation Limited (NYSE:CEA) earned “Sell” rating by Goldman Sachs on Thursday, February 1. The firm has “Buy” rating by Goldman Sachs given on Wednesday, April 6. JP Morgan upgraded China Eastern Airlines Corporation Limited (NYSE:CEA) on Wednesday, September 9 to “Overweight” rating.

The stock decreased 6.02% or $0.34 during the last trading session, reaching $5.31. About 215,822 shares traded. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 0.20% since March 3, 2017 and is downtrending. It has underperformed by 16.90% the S&P500.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $174.23 million. The companyÂ’s drug candidate for the treatment of AlzheimerÂ’s disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.